Beijing Tiantan Biological Products (SHSE:600161) Other Current Liabilities: ¥192 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600161 Beijing Tiantan Biological Products Corp Ltd SHSE:600161
68 GF Score
Price ¥12.56
GF Value ¥22.98
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tiantan Biological Products Other Current Liabilities?

Beijing Tiantan Biological Products SHSE:600161 +2.36% 68 Other Current Liabilities is ¥192 Mil as of Mar. 2026. GuruFocus rates SHSE:600161 with a GF Score™ of 68/100 and a GF Value™ of ¥22.98 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Beijing Tiantan Biological Products's other current liabilities for the quarter that ended in Mar. 2026 was ¥192 Mil.

Beijing Tiantan Biological Products's quarterly other current liabilities increased from Sep. 2025 (¥204 Mil) to Dec. 2025 (¥211 Mil) but then declined from Dec. 2025 (¥211 Mil) to Mar. 2026 (¥192 Mil).

Beijing Tiantan Biological Products's annual other current liabilities declined from Dec. 2023 (¥368 Mil) to Dec. 2024 (¥220 Mil) and declined from Dec. 2024 (¥220 Mil) to Dec. 2025 (¥211 Mil).

Beijing Tiantan Biological Products Other Current Liabilities Related Terms

Beijing Tiantan Biological Products Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Beijing Tiantan Biological Products's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tiantan Biological Products Other Current Liabilities Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 221.64 307.66 367.65 219.56 211.12

Beijing Tiantan Biological Products Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 199.39 183.18 204.26 211.12 191.56
SHSE:600161
68GF Score
Beijing Tiantan Biological Products Corp Ltd SHSE:600161
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tiantan Biological Products Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥192 Mil mean?
Beijing Tiantan Biological Products (SHSE:600161) has a Other Current Liabilities of ¥192 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Beijing Tiantan Biological Products.
Is Beijing Tiantan Biological Products' Other Current Liabilities too high?
Beijing Tiantan Biological Products' current Other Current Liabilities is ¥192 Mil. Overall, Beijing Tiantan Biological Products has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Other Current Liabilities compare to VRTX and REGN?
Beijing Tiantan Biological Products' Other Current Liabilities of ¥192 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Beijing Tiantan Biological Products. Beijing Tiantan Biological Products's current Other Current Liabilities is ¥192 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.98, compared to a current price of ¥12.56 — trading 45.3% below its estimated fair value. The current Other Current Liabilities is ¥192 Mil. Beijing Tiantan Biological Products' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Other Current Liabilities is ¥192 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued. The current stock price of ¥12.56 is trading 45.3% below its estimated GF Value™ of ¥22.98. GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.

Key valuation signals for SHSE:600161:

  • Other Current Liabilities: ¥192 Mil
  • GF Value™: ¥22.98 vs. price of ¥12.56 (45.3% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Tiantan Biological Products Business Description

Address No. 2, Shuangqiao Road, Chaoyang District, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
68GF Score

Get the complete analysis for SHSE:600161

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.56
Price
¥22.98
GF Value